...Astellas was formed in 2005 through the merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. Fujisawa... ...exited the cardiovascular space since the company was formed in 2005 from the merger between Fujisawa Pharmaceutical Co. Ltd....
...The 2004 merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. to form Astellas Pharma Inc... ...FDA approved in November to treat cutaneous T cell lymphoma (CTCL). Gloucester in-licensed Istodax from Fujisawa...
...cheaper and faster than big pharma or medium-sized biotech." Gloucester in-licensed Istodax in 2004 from Fujisawa Pharmaceutical Co. Ltd.... ...form Astellas Pharma Inc. (Tokyo:4503). "We were in the right place at the right time, Fujisawa... ...for CTCL and PTCL by NCI under a Cooperative Research and Development Agreement (CRADA) with Fujisawa...
...Astellas was formed in 2005 through the merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. Fujisawa... ...exited the cardiovascular space since the company was formed in 2005 from the merger between Fujisawa Pharmaceutical Co. Ltd....
...The 2004 merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. to form Astellas Pharma Inc... ...FDA approved in November to treat cutaneous T cell lymphoma (CTCL). Gloucester in-licensed Istodax from Fujisawa...
...cheaper and faster than big pharma or medium-sized biotech." Gloucester in-licensed Istodax in 2004 from Fujisawa Pharmaceutical Co. Ltd.... ...form Astellas Pharma Inc. (Tokyo:4503). "We were in the right place at the right time, Fujisawa... ...for CTCL and PTCL by NCI under a Cooperative Research and Development Agreement (CRADA) with Fujisawa...